“a favorable trend”

19.7 months; HR 0.80; p = 0.018) and a favorable trend in OS (54.3 vs. 48.3 months) compared to those receiving the NACT-first sequence [ 17 ].

Additionally, an exploratory study involving hepatocellular carcinoma patients treated with sorafenib showed a favorable trend in the prophylactic use of topical steroids compared to the non-application group; however, no statistically significant difference was observed [ 14 ], and its effectiveness has not been demonstrated.

For multimorbid patients (at least three medical problems), there was a favorable trend without reaching statistical significance (HR = 0.77, 95% CI 0.66–0.89; p-interaction = 0.18), which means no presence of effect modification in this subgroup.

The administration of anamorelin as a second-line or earlier treatment resulted in significant appetite improvement and BW gain at 3 weeks, with a favorable trend also observed in appetite improvement and BW gain at 12 weeks.

Additionally, a descriptive analysis of OS indicated a favorable trend in both the PD-L1-positive and intention-to-treat (ITT) populations.

Although these differences were not statistically significant (PFS: p = 0.225, OS: p = 0.939), a favorable trend was observed in the low‐dose aspirin group.

Moreover, there is a favorable trend in AHT group, which may be due to improved reperfusion after thrombolysis.

A recent study among UK participants [29] demonstrated a favorable trend in publicly provided psychotherapy and SES indicating that the treatment needs of those with the highest risk were better met in the public sector than previously.

Despite a favorable trend of increased SLNB (14.9 to 54.2%) with decreased ALND (29.5 to 9.1%) over the time frame of our study, practice patterns nevertheless do not adhere to NCCN and ASCO guidelines regarding axillary evaluation, and demonstrate variation by patient ages, tumor size, geographic location, and practice facility type.

Plays originating from high-pressure recovery showed a favorable trend toward shooting on-target.

The results for the secondary endpoints showed a favorable trend of therapeutic hypothermia for an anticonvulsant effect.

They also demonstrated a favorable trend of increased volume share by high-volume surgeons and hospitals in the last 20 years.

34 In the TAKT study (Takayasu Arteritis Treated With Tocilizumab), a double-blind phase 3 RCT, there was a favorable trend toward tocilizumab over placebo for time to relapse, the primary end point; the relapse rate was higher in the placebo arm (53% versus 23%). 22 In the longer open-label follow-up in which all patients received tocilizumab for 96 weeks, disease stabilization was observed in 70% and improvement was seen in 20%. 35 One challenge is that routinely measured acute-phase reactants become unreliable indicators of disease flare in patients receiving tocilizumab.

Conversely, the RA pattern maintained a favorable trend towards risk reduction even among those with comorbidities (Hypertension: HR = 0.75; CKD: HR = 0.59), suggesting that regular physical activity may be necessary to be associated with lower risk in populations with compromised metabolic or renal health.

In our study, survival curves divide in the early phase and remain almost parallel up to 36 months from baseline, with a favorable trend up to 5 years of follow-up.

Our clinical findings indicate that, compared with the conventional I-shaped suture, the V-shaped technique achieved comparable outcomes in pain relief and functional recovery, while demonstrating a favorable trend in patient satisfaction and recurrence rate.

The supplementation of carnosine exhibited a favorable trend towards improved cognitive performance in 3xTg-AD mice, as evidenced by the reduced latency to locate the platform [ 208 ].

PT for EBC showed a favorable trend for OS compared with XT, but no clear superiority was observed.

Specifically, at 12 months postoperatively, the rates were 29.0% in the Lap group and 17.8% in the Ro group, indicating a favorable trend for Ro surgery.

Consequently, while a favorable trend was observed for osimertinib, the analysis was underpowered to detect statistically significant differences in outcomes.

Of note, both in the unmatched population and in the two models derived from PSM, M/V showed a favorable trend on mortality over M/V compared with C/A in patients with septic shock and under mechanical ventilation.

24 reported a favorable trend for NIF, while the other 3 studies favored AMD.

Third, although the power analysis revealed a favorable result, further studies with a larger sample size may reveal different findings because there was a favorable trend toward the ketorolac group in this research, though it was not statistically significant.

A retrospective comparative analysis in 550 patients (REGOTAS) ( 11 ) suggested that regorafenib should be given first in patients aged <65 years, but TAS-102 in patients aged ≥65 years, based on a favorable trend of OS.

Despite the lack of statistical significance, this observed reduction reflects a favorable trend toward improved microvascular outcomes with semaglutide and is clinically relevant, as the prevention of microvascular outcomes is a critical concern in the management of T2D.